Portfolio News

 

   
December 2014
Oncoethix Exit
SV Life Sciences Fund V notes that Merck acquired Oncoethix from its owners, SV Life Sciences and others, for an upfront payment of $110m. Additional milestone payments of up to $265m are contingent upon clinical and regulatory events being achieved. Oncoethix is a clinical stage biotechnology company developing innovative cancer drugs. . Merck Press Release ...

Read more

Team - Kate Bingham, Michael Carter
July 8, 2014
Michael Balmuth Joins SV Life Sciences as Partner
Michael Balmuth Joins SV Life Sciences as Partner Firm Adds Deep Healthcare IT Experience to Healthcare Services Team   BOSTON, MA; SAN FRANCISCO CA; LONDON, UK (July 8, 2014): SV Life Sciences ("SVLS"), a leading, international life sciences venture capital firm, today announced the appointment of Michael Balmuth as Partner.   Mr. Balmuth joins SVLS’ Healthcare Services team, a highly experienced group that looks to partner with accomplished management teams with ...

Read more

June 2, 2014
SV Life Sciences Appoints Three New Venture Partners
Firm Adds Significantly to Strength of Biotech Investment Team   BOSTON, MA, SAN FRANCISCO, CA, LONDON, UK (June 2, 2014): SV Life Sciences ("SVLS"), a leading international life sciences venture capital firm, today announced the appointments of Dan Burgess, Dr. Ed Mascioli and Dr. Michael Mendelsohn as new venture partners.   All three new venture partners will join SVLS’ biotechnology investment team, a highly experienced group investing in truly innovative ...

Read more

May 2014
Urgent Team Holdings
SV Life Sciences Fund V invested in Urgent Team Holdings (UTH) as part of a $10.2m series B financing round. UTH own and operate a regional network of urgent care facilities in the Southern United States.   ...

Read more

Team - Tom Flynn, Eugene Hill
May 2014
Kalvista Pharmaceuticals - Investment
SV Life Sciences Fund IV invested in Kalvista as part of a $5.2m Series A2 extension financing round. Kalvista is a Pharmaceutical and Ophthalmology company developing Plasma Kallikrein inhibitors.   ...

Read more

Team - Kate Bingham, Graham Boulnois
May 2014
Avitide
SV Life Sciences Fund V invested in Avitide as part of a $3.4m Series B financing round. Avitide is a biopharmaceutical company dedicated to the discovery and development of affinity purification products that will improve the fundamental timeframes and economics of commercial bioprocessing.   ...

Read more

Team - Michael Ross
March 31, 2014
Aptiv Exit
SV Life Sciences Fund IV notes that Icon acquired Aptiv from its owners, SV Life Sciences and others for $143.5m. Aptiv is a global development services company focused on enhancing clinical trial decision making and drug and device development through the design, simulation and execution of adaptive clinical trials and a novel statistical sampling approach to risk based monitoring.

Read more

Team - Kate Bingham
January 13, 2014
SV Life Sciences Announces Important Senior Leadership Promotions
SV Life Sciences Announces Important Senior Leadership Promotions BOSTON, MA, SAN FRANCISCO, CA, LONDON, UK (January 13, 2014): SV Life Sciences ("SVLS"), a leading international life sciences venture capital firm, today announced the appointments of Eugene Hill as Chairman, Paul LaViolette as Managing Partner and Chief Operating Officer, Tom Flynn as Managing Partner and Hamish Cameron as Operating Partner.

Read more

Team - James Garvey, Hamish Cameron, Tom Flynn, Eugene Hill, Paul LaViolette
January 2014
Thesan Pharmaceticals
SV Life Sciences V invested in Thesan Pharmaceuticals, a dermatology company focused on therapeutics for the treatment of atopic dermatitis and acne, as part of a $49m series B financing round.  ...

Read more

Team - Michael Ross
January 2014
Maestro Healthcare Technology Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in Maestro Healthcare, Technology-enabled healthcare service company that sells defined contribution plans to employers via private exchange as part of a seed loan financing round. ...

Read more

Team - Tom Flynn, Eugene Hill
January 2014
AqueSys Investment
SV Life Sciences notes that SV Life Sciences Fund V invested in AqueSys, maker of proprietary implants for glaucoma-related vision loss, the world’s No. 2 cause of blindness as part of a $42m series D financing round.  ...

Read more

Team - David Guyer, David Milne

⇧ Back to top